IN2012DN03449A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03449A IN2012DN03449A IN3449DEN2012A IN2012DN03449A IN 2012DN03449 A IN2012DN03449 A IN 2012DN03449A IN 3449DEN2012 A IN3449DEN2012 A IN 3449DEN2012A IN 2012DN03449 A IN2012DN03449 A IN 2012DN03449A
- Authority
- IN
- India
- Prior art keywords
- heteroary
- alkyl
- formula
- disclosed
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25359009P | 2009-10-21 | 2009-10-21 | |
| PCT/US2010/053142 WO2011049917A1 (en) | 2009-10-21 | 2010-10-19 | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03449A true IN2012DN03449A (show.php) | 2015-10-23 |
Family
ID=43126891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3449DEN2012 IN2012DN03449A (show.php) | 2009-10-21 | 2010-10-19 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9056858B2 (show.php) |
| EP (1) | EP2491028B1 (show.php) |
| JP (1) | JP5542946B2 (show.php) |
| KR (1) | KR20120087923A (show.php) |
| CN (1) | CN102666526A (show.php) |
| AP (1) | AP2012006204A0 (show.php) |
| AU (1) | AU2010308277A1 (show.php) |
| BR (1) | BR112012009331A2 (show.php) |
| CA (1) | CA2778060A1 (show.php) |
| CL (1) | CL2012000967A1 (show.php) |
| CO (1) | CO6531488A2 (show.php) |
| DK (1) | DK2491028T3 (show.php) |
| EA (1) | EA021015B1 (show.php) |
| EC (1) | ECSP12011904A (show.php) |
| ES (1) | ES2444780T3 (show.php) |
| GE (1) | GEP20146103B (show.php) |
| HR (1) | HRP20140213T1 (show.php) |
| IL (1) | IL218823A0 (show.php) |
| IN (1) | IN2012DN03449A (show.php) |
| MA (1) | MA33675B1 (show.php) |
| MX (1) | MX2012004644A (show.php) |
| NZ (1) | NZ599132A (show.php) |
| PE (1) | PE20121433A1 (show.php) |
| PH (1) | PH12012500775A1 (show.php) |
| PL (1) | PL2491028T3 (show.php) |
| PT (1) | PT2491028E (show.php) |
| RS (1) | RS53130B (show.php) |
| SI (1) | SI2491028T1 (show.php) |
| TN (1) | TN2012000180A1 (show.php) |
| WO (1) | WO2011049917A1 (show.php) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2285783B1 (en) | 2008-04-29 | 2014-05-21 | Boehringer Ingelheim International GmbH | Indazole compounds as ccr1 receptor antagonists |
| EP2297112B1 (en) | 2008-05-06 | 2013-04-03 | Boehringer Ingelheim International GmbH | Pyrazole compounds as ccr1 antagonists |
| NZ591115A (en) | 2008-09-26 | 2012-10-26 | Boehringer Ingelheim Int | Azaindazole compounds as ccr1 receptor antagonists |
| IN2012DN03449A (show.php) | 2009-10-21 | 2015-10-23 | Boehringer Ingelheim Int | |
| US8927550B2 (en) | 2009-10-27 | 2015-01-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as CCR1 receptor antagonists |
| EP2563787B1 (en) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
| JP5684406B2 (ja) | 2010-12-23 | 2015-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体アンタゴニストとしてのピラゾロピペリジン化合物 |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| PT3131902T (pt) | 2014-04-14 | 2019-09-17 | Boehringer Ingelheim Int | Compostos como moduladores de ror gama |
| CN112707831A (zh) * | 2021-02-05 | 2021-04-27 | 阿里生物新材料（常州）有限公司 | 一种3-（1-氨基环丙基）苯甲酸甲酯的合成方法 |
| WO2025248032A1 (en) | 2024-05-31 | 2025-12-04 | Syngenta Crop Protection Ag | Pesticidally active indazole compounds |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242931A (en) | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
| CA1338625C (en) | 1988-06-09 | 1996-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| UA45944C2 (uk) | 1991-03-28 | 2002-05-15 | Ейсай Ко., Лтд | Гетероцикло-циклічні похідні амінів або їх фармацевтично прийнятні солі, проміжні сполуки, фармацевтична композиція, спосіб інгібування холінестерази, спосіб одержання гетероцикло-циклічних похідних амінів |
| US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| CA2116863A1 (en) | 1992-07-03 | 1994-01-20 | Sumio Yokota | Condensed heterocyclic derivatives and herbicides |
| AU674240B2 (en) | 1993-06-25 | 1996-12-12 | Ihara Chemical Industry Co. Ltd. | Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof |
| JPH10509721A (ja) | 1994-12-06 | 1998-09-22 | メルク シヤープ エンド ドーム リミテツド | ５ｈｔ１レセプターアゴニストとしてのアゼチジン、ピロリジン及びピペリジン誘導体 |
| GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9523583D0 (en) | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| AU1345697A (en) | 1995-12-22 | 1997-07-17 | Du Pont Merck Pharmaceutical Company, The | Novel integrin receptor antagonists |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| JPH101478A (ja) | 1996-06-11 | 1998-01-06 | Kumiai Chem Ind Co Ltd | インダゾールスルホニル尿素誘導体及び除草剤 |
| GB9615449D0 (en) | 1996-07-23 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
| WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
| YU25400A (sh) | 1997-11-04 | 2003-07-07 | Pfizer Products Inc. | Terapeutski aktivna jedinjenja sa indazolom |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| CA2375920A1 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
| WO2001000656A2 (en) | 1999-06-29 | 2001-01-04 | Ortho-Mcneil Pharmaceutical, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| JP4614039B2 (ja) | 2000-03-02 | 2011-01-19 | エヌディーシー・インフラレッド・エンジニアリング・リミテッド | 電磁検出装置 |
| GB0030304D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030305D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030306D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US7058826B2 (en) | 2000-09-27 | 2006-06-06 | Amphus, Inc. | System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment |
| US20020052373A1 (en) | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| ATE455104T1 (de) | 2001-11-01 | 2010-01-15 | Icagen Inc | Pyrazolamide zur anwendung in der behandlung von schmerz |
| WO2008011131A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
| DE60332717D1 (de) | 2002-04-11 | 2010-07-08 | Boehringer Ingelheim Pharma | Heterocyclische amid-derivate als cytokin-inhibitoren |
| CA2482838A1 (en) | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Pyrazole compounds and pharmaceutical compositions containing the compound |
| EP1531822B1 (en) | 2002-06-12 | 2009-08-05 | ChemoCentryx Inc | 1-aryl-4-substituted piperazine derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders |
| CA2494942A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0203825D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| ATE423122T1 (de) | 2003-08-15 | 2009-03-15 | Astrazeneca Ab | Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri) |
| AU2006216917A1 (en) | 2005-02-24 | 2006-08-31 | Merck Sharp & Dohme Corp. | Benzazole potentiators of metabotropic glutamate receptors |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| PL1881823T3 (pl) | 2005-05-17 | 2015-05-29 | Sarcode Bioscience Inc | Kompozycje i sposoby leczenia chorób oczu |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| EP1906965B1 (en) * | 2005-06-22 | 2015-05-06 | ChemoCentryx, Inc. | Azaindazole compounds and methods of use |
| PT1924561E (pt) | 2005-09-01 | 2013-01-16 | Lilly Co Eli | Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dados |
| EP1940394A4 (en) * | 2005-10-25 | 2009-07-08 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| BRPI0806898A2 (pt) | 2007-01-19 | 2015-07-14 | Ardea Biosciences Inc | Inibidores de mek |
| CN101687864A (zh) * | 2007-06-26 | 2010-03-31 | 阿斯利康(瑞典)有限公司 | 作为组织蛋白酶k抑制剂的1-氰基环丙基-衍生物 |
| WO2009037570A2 (en) | 2007-08-10 | 2009-03-26 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| SI2225238T1 (sl) | 2007-11-29 | 2014-12-31 | Boehringer Ingelheim International Gmbh | Derivati amidov 6,7-dihidro-5H-imidazo(1,2-a)imidazol-3-karboksilne kisline |
| EP2285783B1 (en) | 2008-04-29 | 2014-05-21 | Boehringer Ingelheim International GmbH | Indazole compounds as ccr1 receptor antagonists |
| EP2297112B1 (en) | 2008-05-06 | 2013-04-03 | Boehringer Ingelheim International GmbH | Pyrazole compounds as ccr1 antagonists |
| NZ591115A (en) | 2008-09-26 | 2012-10-26 | Boehringer Ingelheim Int | Azaindazole compounds as ccr1 receptor antagonists |
| IN2012DN03449A (show.php) | 2009-10-21 | 2015-10-23 | Boehringer Ingelheim Int | |
| US8927550B2 (en) | 2009-10-27 | 2015-01-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as CCR1 receptor antagonists |
| BR112012013582A2 (pt) | 2009-12-08 | 2016-07-05 | Boehringer Ingelheim Int | processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos |
| EP2563787B1 (en) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
| JP5684406B2 (ja) | 2010-12-23 | 2015-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体アンタゴニストとしてのピラゾロピペリジン化合物 |
-
2010
- 2010-10-19 IN IN3449DEN2012 patent/IN2012DN03449A/en unknown
- 2010-10-19 EP EP10768356.7A patent/EP2491028B1/en active Active
- 2010-10-19 SI SI201030538T patent/SI2491028T1/sl unknown
- 2010-10-19 PL PL10768356T patent/PL2491028T3/pl unknown
- 2010-10-19 DK DK10768356.7T patent/DK2491028T3/da active
- 2010-10-19 RS RS20140024A patent/RS53130B/sr unknown
- 2010-10-19 PH PH1/2012/500775A patent/PH12012500775A1/en unknown
- 2010-10-19 CA CA2778060A patent/CA2778060A1/en not_active Abandoned
- 2010-10-19 PE PE2012000493A patent/PE20121433A1/es not_active Application Discontinuation
- 2010-10-19 NZ NZ599132A patent/NZ599132A/en not_active IP Right Cessation
- 2010-10-19 GE GEAP201012715A patent/GEP20146103B/en unknown
- 2010-10-19 AU AU2010308277A patent/AU2010308277A1/en not_active Abandoned
- 2010-10-19 BR BR112012009331A patent/BR112012009331A2/pt not_active IP Right Cessation
- 2010-10-19 WO PCT/US2010/053142 patent/WO2011049917A1/en not_active Ceased
- 2010-10-19 ES ES10768356.7T patent/ES2444780T3/es active Active
- 2010-10-19 AP AP2012006204A patent/AP2012006204A0/xx unknown
- 2010-10-19 KR KR1020127010143A patent/KR20120087923A/ko not_active Withdrawn
- 2010-10-19 US US13/499,939 patent/US9056858B2/en active Active
- 2010-10-19 MX MX2012004644A patent/MX2012004644A/es active IP Right Grant
- 2010-10-19 JP JP2012535292A patent/JP5542946B2/ja active Active
- 2010-10-19 PT PT107683567T patent/PT2491028E/pt unknown
- 2010-10-19 CN CN2010800578454A patent/CN102666526A/zh active Pending
- 2010-10-19 HR HRP20140213AT patent/HRP20140213T1/hr unknown
- 2010-10-19 EA EA201200602A patent/EA021015B1/ru not_active IP Right Cessation
-
2012
- 2012-03-25 IL IL218823A patent/IL218823A0/en unknown
- 2012-04-16 MA MA34779A patent/MA33675B1/fr unknown
- 2012-04-16 CL CL2012000967A patent/CL2012000967A1/es unknown
- 2012-04-19 TN TNP2012000180A patent/TN2012000180A1/en unknown
- 2012-04-26 CO CO12068976A patent/CO6531488A2/es active IP Right Grant
- 2012-05-16 EC ECSP12011904 patent/ECSP12011904A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9056858B2 (en) | 2015-06-16 |
| JP5542946B2 (ja) | 2014-07-09 |
| PT2491028E (pt) | 2014-02-04 |
| RS53130B (sr) | 2014-06-30 |
| PH12012500775A1 (en) | 2012-11-26 |
| PE20121433A1 (es) | 2012-11-10 |
| HRP20140213T1 (hr) | 2014-04-11 |
| NZ599132A (en) | 2014-05-30 |
| TN2012000180A1 (en) | 2013-12-12 |
| SI2491028T1 (sl) | 2014-03-31 |
| EP2491028B1 (en) | 2013-12-11 |
| MX2012004644A (es) | 2012-05-08 |
| GEP20146103B (en) | 2014-05-27 |
| AU2010308277A1 (en) | 2012-04-26 |
| CN102666526A (zh) | 2012-09-12 |
| EA021015B1 (ru) | 2015-03-31 |
| CO6531488A2 (es) | 2012-09-28 |
| AP2012006204A0 (en) | 2012-04-30 |
| JP2013508376A (ja) | 2013-03-07 |
| US20120270870A1 (en) | 2012-10-25 |
| WO2011049917A1 (en) | 2011-04-28 |
| ECSP12011904A (es) | 2012-10-30 |
| PL2491028T3 (pl) | 2014-05-30 |
| EA201200602A1 (ru) | 2012-12-28 |
| MA33675B1 (fr) | 2012-10-01 |
| BR112012009331A2 (pt) | 2019-09-24 |
| EP2491028A1 (en) | 2012-08-29 |
| IL218823A0 (en) | 2012-06-28 |
| KR20120087923A (ko) | 2012-08-07 |
| CA2778060A1 (en) | 2011-04-28 |
| DK2491028T3 (da) | 2014-01-13 |
| CL2012000967A1 (es) | 2012-09-14 |
| ES2444780T3 (es) | 2014-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN03449A (show.php) | ||
| MX2010004028A (es) | 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona. | |
| NI201100011A (es) | Derivados de piridino - piridinonas, su preparación y su aplicación en terapéutica. | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| PA8774201A1 (es) | Antagonista del receptor | |
| CU20100115A7 (es) | Intermedios útiles para la preparación de derivados de carboxamida como antagonistas del receptor muscarínico | |
| MX2013001234A (es) | Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a. | |
| MX381002B (es) | Compuestos de alquilamido y usos de los mismos. | |
| MX2013005833A (es) | Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa. | |
| EA201290355A1 (ru) | Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1 | |
| UY32553A (es) | Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos | |
| CR11157A (es) | Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica | |
| MA32957B1 (fr) | Derives de quinazolinone utiles comme antagonistes vanilloides | |
| UY30534A1 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii | |
| MX2013006420A (es) | Derivados de aminotriazol hidrolixado como agonistas del receptor de alx. | |
| MX2010004498A (es) | Derivados de ciclohexenoamida y su uso como antagonistas de trpv1. | |
| UA105767C2 (uk) | Аморфна форма протіоконазолу, бактерицидна композиція на її основі, способи їх одержання | |
| EA200700365A1 (ru) | Производные индол-2-карбоксамидина как антагонисты nmda рецептора | |
| UY33528A (es) | Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica | |
| EA201170585A1 (ru) | Производные изохинолинона в качестве антагонистов nk3 | |
| MA32479B1 (fr) | Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques | |
| EA201001870A1 (ru) | Новые кристаллические формы рабепразола натрия | |
| CL2012000159A1 (es) | Procedimiento para la preparacion estereoselectiva de compuestos (trans)- y (cis)-9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, y los compuestos intermediarios considerados. | |
| IN2012DN01661A (show.php) | ||
| MX2012007385A (es) | Derivados de aminoalquilpirimidina como anatagonistas del receptor h4 de histamina. |